Lohmann Rauscher (LR): Personnel Change in Executive Board of LR

Food and Healthcare Press Releases Friday January 26, 2018 09:15
VIENNA and RENGSDORF, Germany--26 Jan--PRNewswire/InfoQuest

In January 2018, a change in the Executive Board of manufacturer and supplier of medical devices, Lohmann & Rauscher (L&R), took place after the former Chief Commercial Officer, Markus Sebastian, had resigned.

The Advisory Board and the CCO mutually agreed that Markus Sebastian is going to leave the Lohmann & Rauscher Corporate Group by the end of January 2018 to pursue new tasks and face new challenges.
Responsibility for the business unit Marketing & Sales will be assumed by Dipl.-Ing. Wolfgang Suessle, President & CEO, on a transitional basis.
Reprint free of charge - specimen copy requested
Lohmann & Rauscher Corporate Group

Lohmann & Rauscher (L&R) is a leading international supplier of high-quality medical devices and hygiene products ranging from conventional dressing material to modern treatment and nursing systems. Created in 1998 through the merger of Lohmann (founded in 1851) and Rauscher (founded in 1899), L&R has more than 160 years' expertise as a reliable solution provider for its customers.

With 4,600 employees, 44 corporate subsidiaries and shareholdings and more than 130 select partners, the company is active in all of the world's key markets. The L&R Group was able to realize a sales of EUR604,2 million in 2017. The L&R headquarters are located in Rengsdorf (Germany) and Vienna (Austria).

L&R's entrepreneurial spirit is reflected in the Group's claim of People.Health.Care.: the human, the health, and the care for both.
Further information on Lohmann & Rauscher (L&R) can be found at:
http://www.lohmann-rauscher.com
Press Contact:
Lohmann & Rauscher International GmbH & Co. KG
Public Relations
Sabrina Klein
Johann-Schorsch-Gasse 4 1140 Vienna
Tel.: +43-1-57670-386 Fax DW: 9386
E-Mail: Sabrina.Klein@at.LRmed.com
http://www.lohmann-rauscher.com
Source: Lohmann & Rauscher

Latest Press Release

Merck and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

Merck and Pfizer Inc. (NYSE: PFE) today announced results from the Phase III JAVELIN Lung 200 trial comparing avelumab* to docetaxel in patients with unresectable, recurrent or metastatic non-small cell lung cancer (NSCLC) whose disease progressed after...

PharmaMar Licenses Fully Synthetic Marine-derived Payloads to Seattle Genetics for Use in Drug Conjugates

PharmaMar (MCE: PHM) has announced today the signing of an exclusive licensing agreement with Seattle Genetics Inc. (SGEN: NASDAQ GS) under which Seattle Genetics receives exclusive worldwide rights to certain PharmaMar proprietary molecules for the...

After multiple failed procedures at other medical institutions, Colorado man successfully treated for Atrial Fibrillation at Texas Cardiac Arrhythmia Institute at St. David#s Medical Center

"I was thinking I was on top of the world," Wiseman said. "I was keeping myself in shape. I was taking care of myself mentally and physically. My relationship was solid." Then, during a routine medical exam while serving in the military in California,...

World#s Leading Health Organizations Release Third Edition of Widely Used Resource on Family Planning

Global Handbook Gives Health-Care Providers Accurate and Practical Guidance for Counseling Clients Family planning is considered a development "best buy" and a life-saving intervention for millions of women and girls. Crucial to the success of family...

ไฟเซอร์ ประเทศไทย สนับสนุนงานประชุมวิชาการด้านโรคมะเร็ง

แผนกมะเร็งวิทยาของบริษัท ไฟเซอร์ (ประเทศไทย) จำกัด (Pfizer Oncology) ให้การสนับสนุนการจัดงานประชุมวิชาการ 'The 5th Ramathibodi-Mayo Clinic Joint Conference: Best Practice in Oncology 2018' ช่วง Lunch Symposium' ในหัวข้อ Continuum of care for ALK positive...

Related Topics